Novartis Net Income Applicable To Common Shares from 2010 to 2026
| NOVN Stock | CHF 120.20 0.24 0.20% |
Net Income Applicable To Common Shares | First Reported 2018-06-30 | Previous Quarter 3.9 B | Current Value 2.4 B | Quarterly Volatility 3 B |
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.2 B, Interest Expense of 619.3 M or Selling General Administrative of 13.9 B, as well as many indicators such as Price To Sales Ratio of 2.91, Dividend Yield of 0.0241 or PTB Ratio of 6.11. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
Novartis | Net Income Applicable To Common Shares |
The evolution of Net Income Applicable To Common Shares for Novartis AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Novartis compares to historical norms and industry peers.
Latest Novartis' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Novartis AG over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Novartis' Net Income Applicable To Common Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Novartis Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | 14,053,847,059 | |
| Geometric Mean | 13,187,266,424 | |
| Coefficient Of Variation | 34.49 | |
| Mean Deviation | 3,898,614,533 | |
| Median | 13,984,000,000 | |
| Standard Deviation | 4,847,329,370 | |
| Sample Variance | 23496602T | |
| Range | 17.3B | |
| R-Value | (0.33) | |
| Mean Square Error | 22413795.9T | |
| R-Squared | 0.11 | |
| Significance | 0.20 | |
| Slope | (312,087,745) | |
| Total Sum of Squares | 375945632.4T |
Novartis Net Income Applicable To Common Shares History
About Novartis Financial Statements
Novartis investors use historical fundamental indicators, such as Novartis' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Novartis. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 14 B | 13.6 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.